Last reviewed · How we verify
NCT04555707
The Maintenance Effect of Enstilar Foam in Combination With Otezla
Phase 4 trial testing Apremilast 30mg in Psoriasis in 30 participants. Status unknown.
30 June 2021
Quick facts
| Lead sponsor | Derm Research, PLLC |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 24 June 2020 |
| Primary completion | 30 June 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Apremilast 30mg — full drug profile →
- calcipotriene and betamethasone dipropionate
Conditions studied
- Psoriasis — all drugs for Psoriasis →
Sponsor
Derm Research, PLLC — full company profile →
Who can join
18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, open-label study. Approximately 30 qualified subjects will be enrolled in a study lasting 20 weeks which investigates the effect of Enstilar used in combination with Otezla to treat psoriasis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04555707
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Apremilast 30mg
Trials testing the same drug.
- NCT05926882 — Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi. · Phase 4 · completed
- NCT06032858 — Efficacy and Safety of Apremilast in Psoriasis · Phase 4 · completed
- NCT03741933 — Apremilast and Moderate to Severe Chronic Hand Dermatitis · Phase 4 · withdrawn
- NCT03690544 — Apremilast for RAS · Phase 4 · completed
- NCT03168256 — CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis · Phase 3 · completed
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
- NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
- NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
- NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
- NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
Other Derm Research, PLLC trials
Trials by the same sponsor.
- NCT04555525 — A Pilot Study on the Use of Seysara for Rosacea · Phase 4 · completed
- NCT03457636 — The Use of Oracea and Epiduo Forte in Severe Acne Patients · Phase 4 · completed
- NCT03848871 — The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients · Phase 4 · completed
- NCT03402893 — The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04555707 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Derm Research, PLLC
- Last refreshed: 9 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04555707.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing